title: Braf V600E mutation in melanoma: translational current scenario.
abstract: Melanoma was one of the translational cancer examples in clinic, including target therapy related to specific biomarkers impacting in the outcome of melanoma patients. Melanomagenesis involved a wide variety of mutations during his evolution; many of these mutated proteins have a kinase activity. One of the most cited proteins in melanoma is BRAF (about 50-60 % of melanomas harbors activating BRAF mutations), for these the most common is a substitution of valine to glutamic acid at codon 600 (p.V600E). Therefore, the precise identification of this underlying somatic mutation is essential; knowing the translational implications has opened a wide view of melanoma biology and therapy.
authors.affiliation: Translational Medicine Laboratory, National Cancer Institute, San Fernando N.22, CP 14080, Mexico City, Mexico.
authors.forename: J A
authors.initials: JA
authors.lastname: Guadarrama-Orozco
authors.affiliation: Translational Medicine Laboratory, National Cancer Institute, San Fernando N.22, CP 14080, Mexico City, Mexico.
authors.forename: A
authors.initials: A
authors.lastname: Ortega-Gómez
authors.affiliation: Translational Medicine Laboratory, National Cancer Institute, San Fernando N.22, CP 14080, Mexico City, Mexico. betzabe100@yahoo.com.
authors.forename: E B
authors.initials: EB
authors.lastname: Ruiz-García
authors.affiliation: Laboratory of Translational Cancer Research and Cellular Therapy, Oncology Hospital, Medical Center Siglo XXI, Mexico City, Mexico.
authors.forename: H
authors.initials: H
authors.lastname: Astudillo-de la Vega
authors.affiliation: National Cancer Institute, Mexico City, Mexico.
authors.forename: A
authors.initials: A
authors.lastname: Meneses-García
authors.affiliation: Genomics Sciences Program, Autonomous University of Mexico City, Mexico City, Mexico.
authors.forename: C
authors.initials: C
authors.lastname: Lopez-Camarillo
mesh_terms: D019008:Drug Resistance, Neoplasm / Q000235:genetics; D006801:Humans; D008545:Melanoma / Q000235:genetics*; D009154:Mutation; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D057170:Translational Research, Biomedical
chemical_list: C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf
keywords: BRAF; Inhibitor resistance; Melanoma; V600E
references.citation: Trends Pharmacol Sci. 2015 Sep;36(9):587-95
references.pmid: 26162965
references.citation: Cancer Res. 2006 Oct 1;66(19):9483-91
references.pmid: 17018604
references.citation: Eur J Cancer. 2012 Jan;48(1):94-100
references.pmid: 21788131
references.citation: PLoS One. 2011;6(12 ):e28973
references.pmid: 22194965
references.citation: Clin Cancer Res. 2002 Nov;8(11):3468-74
references.pmid: 12429636
references.citation: N Engl J Med. 2012 Feb 23;366(8):707-14
references.pmid: 22356324
references.citation: PLoS One. 2013 Aug 20;8(8):e70826
references.pmid: 23976959
references.citation: Clin Cancer Res. 2014 Jul 1;20(13):3446-57
references.pmid: 24812408
references.citation: Nature. 2010 Dec 16;468(7326):968-72
references.pmid: 21107320
references.citation: Melanoma Res. 2006 Dec;16(6):471-8
references.pmid: 17119447
references.citation: J Invest Dermatol. 2010 Jan;130(1):241-8
references.pmid: 19571821
references.citation: Clin Cancer Res. 2012 Jun 15;18(12):3242-9
references.pmid: 22535154
references.citation: Nature. 2002 Jun 27;417(6892):949-54
references.pmid: 12068308
references.citation: Clin Cancer Res. 2013 Feb 1;19(3):598-609
references.pmid: 23095323
references.citation: N Engl J Med. 2005 Nov 17;353(20):2135-47
references.pmid: 16291983
references.citation: Cancer Discov. 2012 Sep;2(9):791-7
references.pmid: 22798288
references.citation: Nat Med. 2013 Nov;19(11):1401-9
references.pmid: 24202393
references.citation: Curr Biol. 2005 Feb 8;15(3):249-54
references.pmid: 15694309
references.citation: Nature. 2012 Jul 26;487(7408):505-9
references.pmid: 22763448
references.citation: Clin Cancer Res. 2003 Aug 15;9(9):3362-8
references.pmid: 12960123
references.citation: Nat Genet. 2003 Jan;33(1):19-20
references.pmid: 12447372
references.citation: Am J Surg Pathol. 2013 Jan;37(1):61-5
references.pmid: 23026937
references.citation: Br J Cancer. 2011 Jul 12;105(2):327-8
references.pmid: 21694724
references.citation: N Engl J Med. 2010 Aug 26;363(9):809-19
references.pmid: 20818844
references.citation: Nat Commun. 2012 Mar 06;3:724
references.pmid: 22395615
references.citation: J Clin Oncol. 2011 Apr 1;29(10):1239-46
references.pmid: 21343559
references.citation: Lancet Oncol. 2013 Mar;14(3):249-56
references.pmid: 23414587
references.citation: Nat Rev Mol Cell Biol. 2004 Nov;5(11):875-85
references.pmid: 15520807
references.citation: Nature. 2010 Sep 30;467(7315):596-9
references.pmid: 20823850
references.citation: Cell. 2004 Mar 19;116(6):764-6
references.pmid: 15035978
references.citation: Melanoma Res. 2015 Feb;25(1):9-14
references.pmid: 25051202
references.citation: Br J Dermatol. 2011 Apr;164(4):776-84
references.pmid: 21166657
references.citation: Sci Signal. 2010 Nov 23;3(149):ra84
references.pmid: 21098728
references.citation: Cell. 2004 Mar 19;116(6):855-67
references.pmid: 15035987
references.citation: BMC Cancer. 2014 Jan 10;14 :13
references.pmid: 24410877
references.citation: N Engl J Med. 2011 Jun 30;364(26):2507-16
references.pmid: 21639808
references.citation: Ann Oncol. 2015 Sep;26(9):1980-7
references.pmid: 26037795
references.citation: Acta Neuropathol. 2011 Jul;122(1):11-9
references.pmid: 21638088
references.citation: Am J Dermatopathol. 2014 Jan;36(1):68-73
references.pmid: 23782679
references.citation: Lancet. 2012 Jul 28;380(9839):358-65
references.pmid: 22735384
references.citation: J Transl Med. 2013 Aug 29;11:202
references.pmid: 23987572
references.citation: Cancer Res. 2011 Apr 1;71(7):2750-60
references.pmid: 21317224
references.citation: Br J Cancer. 2013 Nov 26;109(11):2833-41
references.pmid: 24196789
references.citation: Ethn Dis. 2010 Autumn;20(4):353-8
references.pmid: 21305821
references.citation: Mol Cancer Ther. 2008 Sep;7(9):2876-83
references.pmid: 18790768
references.citation: Cancer Cell. 2010 Dec 14;18(6):683-95
references.pmid: 21156289
references.citation: Clin Cancer Res. 2011 Jan 15;17(2):229-35
references.pmid: 20975100
references.citation: Biochem Pharmacol. 2014 Feb 1;87(3):381-9
references.pmid: 24291778
references.citation: PLoS Med. 2008 Jun 3;5(6):e120
references.pmid: 18532874
references.citation: N Engl J Med. 2012 Nov;367 (18):1694-703
references.pmid: 23020132
references.citation: Nature. 2010 Dec 16;468(7326):973-7
references.pmid: 21107323
references.citation: Clin Cancer Res. 2003 Dec 15;9(17):6483-8
references.pmid: 14695152
references.citation: Clin Cancer Res. 2013 Sep 1;19(17):4868-78
references.pmid: 23833299
references.citation: J Natl Cancer Inst. 2003 Dec 17;95(24):1878-90
references.pmid: 14679157